Merck & Company, Inc. (MRK) Financials
MRK Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2024-03-31 | 106.7 billion | 69.0 billion |
2023-12-31 | 106.7 billion | 69.0 billion |
2023-09-30 | 106.7 billion | 65.4 billion |
2023-06-30 | 104.5 billion | 65.7 billion |
MRK Free Cash Flow and Stock based compensation
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2024-03-31 | -743.0 million | 167.0 million |
2023-12-31 | -743.0 million | 167.0 million |
2023-09-30 | 6.8 billion | 164.0 million |
2023-06-30 | 2.7 billion | 169.0 million |
MRK Net Income
Date | Net Income |
---|---|
2024-03-31 | -1.2 billion |
2023-12-31 | -1.2 billion |
2023-09-30 | 4.8 billion |
2023-06-30 | -6.0 billion |
MRK Cash and Debt
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2024-03-31 | 7.2 billion | - | - |
2023-12-31 | 7.2 billion | - | - |
2023-09-30 | 8.8 billion | 34.0 billion | - |
2023-06-30 | 6.4 billion | 34.1 billion | - |
MRK Shares Outstanding
MRK Expenses
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2024-03-31 | 989.0 million | 8.8 billion | 451.0 million | 2.3 billion |
2023-12-31 | 989.0 million | 8.8 billion | 2.8 billion | - |
2023-09-30 | 902.0 million | 3.3 billion | 2.5 billion | - |
2023-06-30 | 965.0 million | 13.3 billion | 2.6 billion | - |
MRK Cost of Revenue
Date | Revenue | Cost of Revenue |
---|---|---|
2024-03-31 | 14.6 billion | 3.3 billion |
2023-12-31 | 14.6 billion | 3.3 billion |
2023-09-30 | 16.0 billion | 4.3 billion |
2023-06-30 | 15.0 billion | 4.0 billion |
MRK
List: Contenders
Price: $130.38
Dividend Yield: 0.02%
Forward Dividend Yield: 2.41%
Payout Ratio: 2200.00%
Dividend Per Share: 3.08 USD
Earnings Per Share: 0.91 USD
P/E Ratio: 70.23
Exchange: NYQ
Sector: Healthcare
Industry: Drug Manufacturers - General
Volume: 7.8 million
Ebitda: 2.3 billionMarket Capitalization: 323.0 billion
Average Dividend Frequency: 4
Years Paying Dividends: 63
DGR3: 8.71%
DGR5: 9.43%
DGR10: 5.84%
DGR20: 10.47%